Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

  • ID: 3978520
  • Report
  • Region: Global
  • 183 Pages
  • GBI Research
1 of 5
Global Revenues for the Cancer Vaccines Market are Forecast to grow at a CAGR of 16.93%, from $2.5 Billion in 2015 to $7.5 Billion in 2022

FEATURED COMPANIES

  • Amgen
  • Bavarian Nordic
  • Bluebird Bio
  • GSK
  • Juno Therapeutics
  • Kite Pharma
  • MORE

Cancer is anticipated to become increasingly prevalent due to aging populations and rising levels of obesity in the developed world. Cancer vaccines are being developed as a method of preventing certain types of cancer and as therapeutic treatments to treat existing cancers across a range of oncology indications. They can be used as stand-alone therapies or in combination with traditional cancer therapeutics such as chemotherapy and surgery.

Cancer vaccines are not perceived to have as promising a level of commercial potential as immune checkpoint inhibitors. These are a relatively new class of treatments, with the first FDA approval being granted in 2011, for Yervoy. The immune system depends on multiple checkpoints or ‘immunological brakes’ to avoid over activation of the immune system on healthy cells, and tumor cells often exploit these checkpoints to escape detection by the immune system. Immune checkpoint inhibitors block the proteins involved in the mechanisms behind immune evasion, allowing T-cells and the immune system to better destroy cancer cells.

Adam Bradbury, explains: “The cancer vaccines space will see such impressive growth over next decade for a number of reasons. There is a fairly large cancer vaccine pipeline, with over 1,200 products being developed, accounting for almost 17% of the overall oncology pipeline, the largest of any therapy area.”

Generic penetration is currently non-existent in the cancer vaccines market, further aiding market growth. Indeed, therapeutic vaccines are a relatively new form of cancer treatment, with the first FDA approval granted to Provence in 2010. Prophylactic vaccines have not yet faced patent expiry, meaning the threat of generics/biosimilars restricting revenue growth in this market during the forecast period is low.

The report “Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19” provides an introduction to oncology, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications.

In depth, it provides the following:

  • Provides an overview of the oncology vaccines marketed products landscape, including profiles of key marketed products, and revenue projections for each of these drugs.
  • Analyzes the oncology vaccines pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: cervical, liver, and prostate cancer and melanoma. The clinical trial landscape is also examined, with an emphasis on trends in clinical trial failure rates, duration and size.
  • Assesses the company landscape in oncology vaccines, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company’s pipeline portfolio and total revenues.
  • Analyzes trends in co-development and licensing deals relating to oncology vaccines products. Some of the most prominent deals are discussed in detail.

Companies mentioned in this report: Merck & Co, GSK, Novartis, Kite Pharma, Amgen, Juno Therapeutics, Valeant Pharma, Bluebird Bio, Bavarian Nordic.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen
  • Bavarian Nordic
  • Bluebird Bio
  • GSK
  • Juno Therapeutics
  • Kite Pharma
  • MORE

1 Table of Contents

2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Etiology and Pathophysiology
2.3.1 Etiology
2.3.2 Cancer Pathophysiology
2.3.3 Virus Pathophysiology
2.4 Epidemiology Patterns - Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates
2.4.1 Cervical Cancer
2.4.2 Liver Cancer
2.4.3 Melanoma
2.4.4 Prostate Cancer
2.5 Co-morbidities and Complications
2.6 Treatment
2.6.1 Surgery and Radiation Therapy
2.6.2 Chemotherapy
2.6.3 Hormonal Therapies
2.6.4 Targeted Therapies
2.6.5 Types of Cancer Vaccines

3 Key Marketed Products
3.1 Overview
3.2 Gardasil/Gardasil 9
3.3 Provenge
3.4 Cervarix
3.5 Imlygic
3.6 DCVax-L
3.7 Recombivax HB
3.8 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.2.1 Therapeutic Vaccine Molecule Type and Development Stage
4.2.2 Prophylactic Vaccine Molecule Type and Development Stage
4.2.3 Key Oncology Indications by Molecule Type and Development Stage
4.3 Pipeline by Molecular Targets and Indication
4.3.1 Therapeutic Vaccine Molecular Targets
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.5 Conclusion
4.5 Assessment of Key Pipeline Products
4.5.1 Tisagenlecleucel-T (CTL-019) - Novartis
4.5.2 KTE-C19 - Kite Pharma
4.5.3 JCAR017 - Juno Therapeutics
4.5.4 JCAR015 - Juno Therapeutics
4.5.5 bb-2121 - Bluebird Bio
4.5.6 Prostvac - Bavarian Nordic
4.5.7 Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Kite Pharma
4.5.8 Conclusion

5 Multi-scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Prophylactic and Therapeutic Vaccine Market Split
5.3 Revenue Forecast by Molecular Target
5.3.1 HPV L1 Major Capsid Protein
5.3.2 Hepatitis B Surface Antigen
5.3.3 Cluster of Differentiation
5.3.4 Granulocyte Macrophage Colony Stimulating Factor
5.3.5 Tumor Necrosis Factor Receptor Superfamily Member
5.3.6 Prostatic Acid Phosphatase

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Merck & Co - How Will Cancer Vaccine Revenues Be Affected by Recombivax HB’s Patent Expiry?
6.1.2 GSK - How Will Its Prophylactic Vaccines Fair Against Merck & Co’s Competitors?
6.1.3 Novartis - How Will This Top 20 Company Perform in The Cancer Vaccines Market?
6.1.4 Kite Pharma - Could it Develop a Blockbuster?
6.1.5 Amgen - How Will Recent Approval Imlygic Perform?
6.1.6 Juno Therapeutics - Great Potential for its CD19 Targeting Therapies
6.1.7 Valeant Pharma - Uncertain Times and Financial Difficulties
6.1.8 Bluebird Bio - How Will This Small Company Perform in the Cancer Vaccines Market?
6.1.9 Bavarian Nordic - How Will Prostvac Perform?
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region and Value
7.1.2 Deals by Indication, Stage of Development and Value
7.1.3 Deals by Molecule Type, Molecular Target and Value
7.1.4 Table for Licensing Deals with Disclosed Values
7.2 Co-development Deals
7.2.1 Deals by Region and Value
7.2.2 Deals by Indication, Stage of Development and Value
7.2.3 Deals by Molecule Type, Molecular Target and Value
7.2.4 Table for Co-development Deals With a Disclosed Value

8 Appendix
8.1 References
8.2 Table of All Pipeline Products
8.3 Abbreviations
8.4 Methodology
8.4.1 Coverage
8.4.2 Secondary Research
8.4.3 Market Size and Revenue Forecasts
8.4.4 Pipeline Analysis
8.4.5 Competitive Landscape

List of Tables

Table 1: Cancer Vaccines Market, Global, Symptoms of Key Indication Cancers, 2016
Table 2: Cancer Vaccines Market, Global, Infectious Agents and Associated Cancers, 2016
Table 3: Cancer Vaccines Market, Global, Epidemiology of Key Oncology Indications, 2016
Table 4: Cancer Vaccines Market, Complications Associated with Cervical, Liver, Melanoma and Prostate Cancers, 2016
Table 5: Cancer Vaccines Market, Optimal Chemotherapy Usage Rates
Table 6: Cancer Vaccines Market, Global, Approved Indications for Gardasil, 2016
Table 7: Cancer Vaccines Market, Global, Approved Indications for Provenge, 2016
Table 8: Cancer Vaccines Market, Global, Approved Indications for Cervarix, 2016
Table 9: Cancer Vaccines Market, Global, Approved Indications for Imlygic, 2016
Table 10: Cancer Vaccines Market, Global, Approved Indications for DCVax-L, 2016
Table 11: Cancer Vaccines Market, Global, Approved Indications for Recombivax HB, 2016
Table 12: Cancer Vaccines Market, Global, Usage of Prophylactic and Therapeutic Vaccines Across Key Indications, 2016
Table 13: Cancer Vaccines Market, Global, Forecast Revenue by Company, 2015-2022
Table 14: Cancer Vaccines Market, Global, Disclosed Licensing Deals, 2006-2016
Table 15: Cancer Vaccines Market, Global, Disclosed Co-development Deals, 2006-2016
Table 16: Cancer Vaccines, Global, All Pipeline Products, 2016
Table 17: Abbreviations

List of Figures

Figure 1: Cancer Vaccines Market, Major Markets, Treatment Usage Patterns for Cervical Cancer, Patients (‘000), 2015-2022
Figure 2: Cancer Vaccines Market, Major Markets, Treatment Usage Patterns for Liver Cancer, Patients (‘000), 2015-2022
Figure 3: Cancer Vaccines Market, Major Markets, Treatment Usage Patterns for Melanoma, Patients (‘000), 2015-2022
Figure 4: Cancer Vaccines Market, Major Markets, Treatment Usage Patterns for Prostate Cancer, Patients (‘000), 2015-2022
Figure 5: Cancer Vaccines Market, Global, Key Marketed Products and Approved Indications, 2016
Figure 6: Cancer Vaccines Market, Global, Annual Revenues for Gardasil ($bn), 2006-2022
Figure 7: Cancer Vaccines Market, Global, Annual Revenues for Provenge ($m), 2010-2022
Figure 8: Cancer Vaccines Market, Global, Annual Revenues for Cervarix ($m), 2007-2022
Figure 9: Cancer Vaccines Market, Global, Annual Revenues for Imlygic ($m), 2015-2022
Figure 10: Cancer Vaccines Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
Figure 11: Cancer Vaccines Market, Global, Pipeline for Therapeutic Cancer Vaccines by Stage of Development and Molecule Type, 2016
Figure 12: Cancer Vaccines Market, Global, Pipeline for Prophylactic Cancer Vaccines by Stage of Development and Molecule Type, 2016
Figure 13: Cancer Vaccines Market, Global, Pipeline for Key Oncology Indications by Stage of Development, 2016
Figure 14: Cancer Vaccines Market, Global, Pipeline for Key Oncology Indications by Molecule Type, 2016
Figure 15: Cancer Vaccines Market, Global, Pipeline for Therapeutic Vaccines by Indication and Molecular Target, 2016
Figure 16: Cancer Vaccines Market, Global, Pipeline for Prophylactic Vaccines by Indication and Molecular Target, 2016
Figure 17: Cancer Vaccines Market, Global, Pipeline for Key Oncology Indications by Molecular Target, 2016
Figure 18: Cancer Vaccines Market, Global, Clinical Trial Failure Rates by Stage of Development and Overall Clinical Trial Attrition Rate (%), 2006-2016
Figure 19: Cancer Vaccines Market, Global, Clinical Trial Failure Rates by Stage of Development and Indication (%), 2006-2016
Figure 20: Cancer Vaccines Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecule Type (%), 2006-2016
Figure 21: Cancer Vaccines Market, Global, Clinical Trial Failure Rates by Stage of Development and Molecular Target (%), 2006-2016
Figure 22: Cancer Vaccines Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016
Figure 23: Cancer Vaccines Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
Figure 24: Cancer Vaccines Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
Figure 25: Cancer Vaccines Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
Figure 26: Cancer Vaccines Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2016
Figure 27: Cancer Vaccines Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
Figure 28: Cancer Vaccines Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 29: Cancer Vaccines Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 30: Cancer Vaccines Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2016
Figure 31: Cancer Vaccines Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
Figure 32: Cancer Vaccines Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 33: Cancer Vaccines Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 34: Cancer Vaccines Market , Global, Revenue Forecast for Tisagenlecleucel-T ($bn), 2017-2022
Figure 35: Cancer Vaccines Market, Global, Revenue Forecast for KTE-C19 ($bn), 2017-2022
Figure 36: Cancer Vaccines Market, Global, Revenue Forecast for JCAR-017 ($bn), 2017-2022
Figure 37: Cancer Vaccines Market, Global, Revenue Forecast for JCAR-015 ($m), 2018-2022
Figure 38: Cancer Vaccines Market, Global, Revenue Forecast for bb-2121 ($m), 2019-2022
Figure 39: Cancer Vaccines Market, Global, Revenue Forecast for Prostvac ($m), 2016-2022
Figure 40: Cancer Vaccines Market, Global, Revenue Forecast for Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer ($m), 2018-2022
Figure 41: Cancer Vaccines Market, Global, Market Size ($bn), 2015-2022
Figure 42: Cancer Vaccines Market, Global, Market Size ($bn)
Figure 43: Cancer Vaccines Market, Global, Annual Revenue Forecast for Prophylactic and Therapeutic Products ($bn), 2015-2022
Figure 44: Cancer Vaccines Market, Global, Annual Revenue Forecast for HPV L1 Major Capsid Protein ($bn), 2015-2022
Figure 45: Cancer Vaccines Market, Global, Annual Revenue Forecast for Hepatitis B Surface Antigen ($m), 2015-2022
Figure 46: Cancer Vaccines Market, Global, Annual Revenue Forecast for Cluster of Differentiation 19 ($bn), 2017-2022
Figure 47: Cancer Vaccines Market, Global, Annual Revenue Forecast for Granulocyte Macrophage Colony Stimulating Factor ($m), 2016-2022
Figure 48: Cancer Vaccines Market, Global, Annual Revenue Forecast for Tumor Necrosis Factor Receptor Superfamily Member 17 ($m), 2019-2022
Figure 49: Cancer Vaccines Market, Global, Annual Revenue Forecast for Prostatic Acid Phosphatase ($m), 2015-2022
Figure 50: Cancer Vaccines Market, Global, Companies by Type, Cluster by Growth and Market Share, 2015-2022
Figure 51: Cancer Vaccines Market, Global, Company Analysis Matrix, 2016
Figure 52: Cancer Vaccine Market, Global, Forecast Market Share by Company (%), 2015-2022
Figure 53: Cancer Vaccines Market, Global, Companies by Compound Annual Growth Rate (%), 2015-2022
Figure 54: Cancer Vaccines Market, Global, Revenues by Product Type, 2015-2022
Figure 55: Cancer Vaccines Market, Global, Merck & Co Annual Revenue Forecast ($bn), 2015-2022
Figure 56: Cancer Vaccines Market, Global, GSK Annual Revenue Forecast ($m), 2015-2022
Figure 57: Cancer Vaccines Market, Global, Novartis Annual Revenue Forecast ($bn), 2017-2022
Figure 58: Cancer Vaccines Market, Global, Kite Pharma Annual Revenue Forecast ($bn), 2017-2022
Figure 59: Cancer Vaccines Market, Amgen Annual Revenue Forecast ($m), 2016-2022
Figure 60: Cancer Vaccines Market, Juno Therapeutics Annual Revenue Forecast ($bn), 2017-2022
Figure 61: Cancer Vaccines Market, Global, Valeant Annual Revenue Forecast ($m), 2015-2022
Figure 62: Cancer Vaccines Market, Global, Bluebird Bio Annual Revenue Forecast ($m), 2019-2022
Figure 63: Cancer Vaccines Market, Global, Bavarian Nordic Annual Revenue Forecast ($m), 2016-2022
Figure 64: Cancer Vaccines Market, Global, Companies by Type, 2015-2022
Figure 65: Cancer Vaccines Market, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Cancer Vaccine Specialization, 2015-2022
Figure 66: Cancer Vaccines Market, Global, Proportion of Total Company Revenue Attributed to Cancer Vaccines, 2015-2022
Figure 67: Cancer Vaccines Market, Global, Licensing Deals by Region and Value, 2006-2016
Figure 68: Cancer Vaccines Market, Global, Licensing Deals by Indication and Value, 2006-2016
Figure 69: Cancer Vaccines Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016
Figure 70: Cancer Vaccines Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006-2016
Figure 71: Cancer Vaccines Market, Global, Co-development Deals by Region and Value, 2006-2016
Figure 72: Cancer Vaccines Market, Global, Co-development Deals by Indication and Value, 2006-2016
Figure 73: Cancer Vaccines Market, Global, Co-development Deals by Stage of Development and Value, 2006-2016
Figure 74: Cancer Vaccines Market, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen
  • Bavarian Nordic
  • Bluebird Bio
  • GSK
  • Juno Therapeutics
  • Kite Pharma
  • Merck & Co
  • Novartis
  • Valeant Pharma
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll